ArticleThe British journal of surgery2019
Impact of resection margin status on recurrence and survival in pancreatic cancer surgery.
Article in The British journal of surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 5 syntheses or guidelines pooled it, 219 citations in OpenAlex.
- Impact of R0/R1 Margin Status on Overall Survival in Node-Positive Resected Pancreatic Ductal Adenocarcinoma: Meta-Analysis.Annals of surgical oncology · 2026Pooled it
- Tumour-targeted fluorescence-guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research.Clinical and translational medicine · 2026Pooled it
- Misdiagnosis of Suspected Cancer in Pancreatoduodenectomy: A Systematic Review and Prevalence Mata-Analysis.Journal of gastrointestinal cancer · 2025Pooled it
- Prognostic relevance of the revised R status definition in pancreatic cancer: meta-analysis.BJS open · 2022Pooled it
- Robotic pancreaticoduodenectomy provides better histopathological outcomes as compared to its open counterpart: a meta-analysis.Scientific reports · 2021Pooled it
- Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study.The oncologist · 2025Trial
- Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- FulminantAnnals of hepato-biliary-pancreatic surgery · 2026Article
- Multifrequency magnetic resonance elastography for predicting pancreatic cancer aggressiveness and patient survival.European radiology · 2026Article
- Local Recurrence After Pancreatic Cancer Resection: A Multidisciplinary Review of Risk Factors and Potential Causes, Diagnostic Innovations, Emerging Therapeutic Frontiers, and Prevention Strategies.Current treatment options in oncology · 2026Review
- Robotic-assisted pancreaticoduodenectomy: Portal vein-first vs artery-first approach.Journal of the Chinese Medical Association : JCMA · 2026Article
- Preoperative Gemcitabine/Nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone.Annals of gastroenterological surgery · 2026Article
- ASO Author Reflections: Does Nodal Disease Alone Warrant Adjuvant Radiotherapy after Pancreaticoduodenectomy?Annals of surgical oncology · 2026Article
- Mesopancreas excision in pancreatic ductal adenocarcinoma: recurrence patterns - a single-arm descriptive study.World journal of surgical oncology · 2026Article
- Pancreatic cancer.Nature reviews. Disease primers · 2026Review
- Article
- Protocol for generating a 3D hydrogel-based tumor resection model in vitro using pancreatic cancer cells.STAR protocols · 2026Article
- Identifying intact and fibrotic parenchyma in pancreatic ductal adenocarcinomas using compression optical coherence elastography.Scientific reports · 2026Article
- Clinical Significance of an R1 Resection for Pancreatic Ductal Adenocarcinomas Treated by Intensive FOLFIRINOX Induction-Based Chemotherapy and Extended Pancreatectomies.Annals of surgical oncology · 2026Article
- Emerging role of low-frequency somatic mutations in cancer relapse: from early detection to precision oncology.Frontiers in oncology · 2026Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) is poor and selection of patients for surgery is challenging. This study examined the impact of a positive resection margin (R1) on locoregional recurrence (LRR) and overall survival (OS); and also aimed to identified tumour characteristics and/or technical factors associated with a positive resection margin in patients with PDAC.
methodsPatients scheduled for pancreatic resection for PDAC between 2006 and 2016 were identified from an institutional database. The effect of resection margin status, patient characteristics and tumour characteristics on LRR, distant metastasis and OS was assessed.
resultsA total of 322 patients underwent pancreatectomy for PDAC. A positive resection (R1) margin was found in 129 patients (40·1 per cent); this was associated with decreased OS compared with that in patients with an R0 margin (median 15 (95 per cent c.i. 13 to 17) versus 22 months; P < 0·001). R1 status was associated with reduced time to LRR (median 16 versus 36 (not estimated, n.e.) months; P = 0·002). Disease recurrence patterns were similar in the R1 and R0 groups. Risk factors for early recurrence were tumour stage, positive lymph nodes (N1) and perineural invasion. Among 100 patients with N0 disease, R1 status was associated with shorter OS compared with R0 resection (median 17 (10 to 24) versus 45 (n.e.) months; P = 0·002), whereas R status was not related to OS in 222 patients with N1 disease (median 14 (12 to 16) versus 17 (15 to 19) months after R1 and R0 resection respectively; P = 0·068).
conclusionAlthough pancreatic resection with a positive margin was associated with poor survival and early recurrence, particularly in patients with N1 disease, disease recurrence patterns were similar between R1 and R0 groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.